Hexagon | AutonomouStuff Webinar Showcases How Velodyne’s Velarray H800 and PAEB Solution Can Power Advanced Driver Assistance Systems (ADAS) and Autonomy
8.12.2020 16:00:00 EET | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced Dr. Mircea Gradu, the company’s Senior Vice President of Product and Quality, is the featured speaker at a Hexagon | AutonomouStuff webinar on how lidar solutions can enhance safety in consumer vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005231/en/
Velodyne Lidar’s Velarray H800 solid state lidar sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. (Photo: Velodyne Lidar, Inc.)
The free webinar, called “Automotive-grade solid-state lidar for ADAS and autonomy: Velodyne Velarray H800,” takes place on December 15, 2020 at 2:00 p.m. EST. It is being moderated by Nicole Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff. To register, please click here.
The webinar will focus on the Velarray H800, Velodyne’s newly launched solid state lidar sensor designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The Velarray H800 is a key technology that will be used in systems for powerful vehicle safety, including for Automatic Emergency Braking, Lane Keep Assist and Adaptive Cruise Control.
The webinar will also cover Velodyne’s Pedestrian Automated Emergency Braking (PAEB) solution, which combines proprietary software, called Vella™, with Velodyne’s lidar sensors. Recent pedestrian crash statistics highlight an opportunity for PAEB systems to save thousands of lives annually by improving performance in dark conditions. According to the National Highway Traffic Safety Association, in 2018, 76% of the 6,283 total pedestrian crash fatalities in the U.S. occurred in dark conditions. Adding lidar can help address the risks that current PAEB systems present in frequently failing to protect pedestrians in dark conditions.
To demonstrate how PAEB systems can be achieved by utilizing lidar, Velodyne tested its lidar-based PAEB system against a highly-rated PAEB system built around camera and radar. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested. The combination of Velarray lidar data and Vella processing software dramatically improves PAEB performance, addressing a use case that causes thousands of pedestrian fatalities annually, and strengthening the vehicle’s functional safety achievements. For more information on the testing, please see Velodyne’s recently issued white paper regarding PAEB here.
“Lidar is an essential building block in creating advanced driving systems that improve vehicle, passenger and pedestrian safety. Webinar attendees can hear from a leading industry authority on how the Velarray H800 lidar sensor can help make cars and roadways safer for everyone,” said Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff.
“This webinar will discuss how automakers can significantly improve effectiveness and efficiency of vehicle driver-assist features and full autonomy by employing the Velarray H800. The sensor provides a revolutionary approach to making vehicles smarter and safer,” said Gradu.
Gradu leads Velodyne’s efforts to design, develop and manufacture world-class products compliant with international quality standards and is the 2018 President and Chairman of the Board of the Society of Automotive Engineers (SAE) International. He also is a Professor in the Mechanical and Aerospace Engineering Department at University of California Irvine (UCI), a member of UCI’s Institute for Transportation Studies Leadership Council and a FISITA Council member (International Federation of the Automotive Engineering Societies).
The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in ADAS and autonomy, from Level 2 to Level 5. The sensor’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. It is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA).
About Velodyne Lidar
Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005231/en/
Contact information
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
